--- title: "Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes | PBH Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/291283781.md" description: "Prestige Consumer Healthcare Inc. announced that its subsidiary, Prestige Brands, intends to offer up to $400 million in new senior notes due 2034 via private placement. Net proceeds will be used to redeem all outstanding $400 million of the 5.125% Senior Notes due 2028 at 100% of principal plus accrued interest. The redemption is conditioned on completing this new offering." datetime: "2026-06-30T04:24:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291283781.md) - [en](https://longbridge.com/en/news/291283781.md) - [zh-HK](https://longbridge.com/zh-HK/news/291283781.md) --- # Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes | PBH Stock News See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google Add on Google TARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $400 million in aggregate principal amount of new senior notes due 2034 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries. The Company intends to use the net proceeds from the proposed offering, together with cash on hand, to redeem all $400 million of Prestige Brands’ outstanding 5.125% Senior Notes due 2028 (the “2028 notes”), and to pay related fees and expenses. Prestige Brands expects to give notice of its intention to redeem the 2028 notes pursuant to the indenture governing the 2028 notes, at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest to the date of redemption. The redemption of the 2028 notes is conditioned on the completion of an offering of new unsecured senior notes in an aggregate principal amount of at least $400 million (the “Financing Condition”). Prestige Brands may waive the Financing Condition in its sole discretion. The notes and related guarantees are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes and related guarantees. Any offers of the notes and related guarantees will be made only by means of a private offering memorandum. The notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. **About** **Prestige** **Consumer** **Healthcare** **Inc.** Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat ® and Summer’s Eve ® women’s health products, BC ® and Goody’s ® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden’s ® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste ® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. **Note** **Regarding** **Forward-Looking** **Statements** _This news release contains “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe_ _Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by_ _the_ _use_ _of_ _forward-looking_ _terminology_ _such_ _as “intends,” “expects,” “may,” and “will”_ _(or_ _the_ _negative_ _or_ _other_ _derivatives_ _of_ _each_ _of_ _these_ _terms)_ _or_ _similar terminology. The “forward-looking statements” include, without limitation, statements regarding the Company’s expectations regarding the offering of the notes and the redemption of the 2028 notes. These statements are based on management’s estimates and assumptions with respect to future events and financial_ _performance and_ _are_ _believed to be reasonable,_ _though are inherently uncertain_ _and_ _difficult to predict._ _Actual_ _results_ _could differ materially from those expected as a result of a variety of factors, including general economic and business conditions._ _A discussion of other factors that could_ _cause_ _results to vary_ _is included_ _in the_ _Company’s Annual Report on Form 10-K for the fiscal year_ _ended March_ _31, 2026 and_ _other_ _periodic reports filed with the Securities and Exchange Commission._ Investor Relations Contact 914-524-6819 **irinquiries@prestigebrands.com** Source: Prestige Consumer Healthcare Inc. ### Related Stocks - [PBH.US](https://longbridge.com/en/quote/PBH.US.md) ## Related News & Research - [Prestige Consumer Healthcare (NYSE:PBH) Issues Earnings Results, Beats Expectations By $0.09 EPS](https://longbridge.com/en/news/295308800.md) - [Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook](https://longbridge.com/en/news/295089244.md) - [Renaissance Technologies LLC Has $2.17 Million Stake in Prestige Consumer Healthcare Inc. $PBH](https://longbridge.com/en/news/295507758.md) - [Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio | JAZZ Stock News](https://longbridge.com/en/news/295400495.md) - [Here's when Elon Musk's Starlink internet is worth the steep monthly price - and $350 startup cost](https://longbridge.com/en/news/295424188.md)